Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study
Journal of Clinical Oncology · 10.06.2023 · 41 (17) · 3116-3121
DOI: 10.1200/jco.22.02900 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2023. Verfasst von Matteo Lazzeroni und 22 weiteren Autor:innen. Beteiligte Einrichtung: IEO-European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms, Carcinoma in Situ. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. PURPOSE Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% the recurrence of invasive breast cancer or ductal carcinoma in situ (DCIS), without additional adverse events over placebo. Here, we present the 10-year results. METHODS We randomly assigned 500 women with breast IEN (atypical ductal hyperplasia, lobular carcinoma in situ [LCIS], or hormone-sensitive or unknown DCIS) to low-dose tamoxifen or placebo after surgery with or without irradiation. The primary end point was the incidence of invasive breast cancer or DCIS. RESULTS The TAM-01 population included 500 women (20% atypical ductal hyperplasia, 11% LCIS, and 69% DCIS). The mean (±SD) age at the start of treatment was 54 ± 9 years, and 58% of participants were postmenopausal. After a median follow-up of 9.7 years (IQR, 8.3-10.9 years), 66 breast cancers (15 in situ; 51 invasive) were diagnosed: 25 in the tamoxifen group and 41 in the placebo group (annual rate per 1,000 person-years, 11.3 with tamoxifen v 19.5 with placebo; hazard ratio [HR], 0.58; 95% CI, 0.35 to 0.95; log-rank P = .03). Most recurrences were invasive (77%) and ipsilateral (59%). Regarding contralateral breast cancer incidence, there were six events in the tamoxifen arm and 16 in the placebo arm (HR, 0.36; 95% CI, 0.14 to 0.92; P = .025). The number needed to be treated to prevent one case of breast event with tamoxifen therapy was 22 in 5 years and 14 in 10 years. The benefit was seen across all patient subgroups. There was a significant 50% reduction of recurrence with tamoxifen in the DCIS cohort, which represents 70% of the overall population (HR, 0.50; 95% CI, 0.28 to 0.91; P = .02). No between-group difference in the incidence of serious adverse events was reported during the prolonged follow-up period. CONCLUSION Tamoxifen 5 mg once daily for 3 years significantly prevents recurrence from noninvasive breast cancer after 7 years from treatment cessation without long-term adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IEO-European Institute of Oncology IRCCS, Milan, Italy.
- Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy.
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
- Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
- IRCCS Istituto Tumori "G. Paolo II", Bari, Italy.
ORCID-Profile: Matteo Lazzeroni, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Davide Serrano, Luca Boni, Tania Buttiron Webber, Marianna Fava, Irene M Briata, Fabio Falcini, Patrizia Serra, Franca Avino, Alessia De Simone, Bernardo Bonanni, Andrea DeCensi
Zitieren
APA
Lazzeroni, M., Puntoni, M., Guerrieri-Gonzaga, A., Serrano, D., Boni, L., Buttiron Webber, T., Fava, M., Briata, I. M., Giordano, L., Digennaro, M., Cortesi, L., Falcini, F., Serra, P., Avino, F., Millo, F., Cagossi, K., Gallerani, E., De Simone, A., Cariello, A., …, & DeCensi, A. (2023). Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. Journal of Clinical Oncology, 41(17), 3116-3121. https://doi.org/10.1200/jco.22.02900
Vancouver
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. Journal of Clinical Oncology. 2023;41(17):3116-3121. doi:10.1200/jco.22.02900
BibTeX
@article{Lazzeroni2023,
author = {Lazzeroni, Matteo and Puntoni, Matteo and Guerrieri-Gonzaga, Aliana and Serrano, Davide and Boni, Luca and Buttiron Webber, Tania and Fava, Marianna and Briata, Irene M and Giordano, Livia and Digennaro, Maria and Cortesi, Laura and Falcini, Fabio and Serra, Patrizia and Avino, Franca and Millo, Francesco and Cagossi, Katia and Gallerani, Elisa and De Simone, Alessia and Cariello, Anna and Aprile, Giuseppe and Renne, Maria and Bonanni, Bernardo and DeCensi, Andrea},
title = {Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {17},
pages = {3116--3121},
doi = {10.1200/jco.22.02900}
}
EUVIMED